These findings indicate that AICAR-activated AMPK signaling in liver cells could inhibit the NF-κB, mainly the noncanonical pathway, to relieve liver inflammation and fibrosis, which may be beneficial in treating liver injury or liver cirrhosis triggered by cholestatic liver disease. Here, NFKB1 is linked to Cholestatic liver disease.